BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:survodutide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of survodutide\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07768813-119@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20261208
DTEND;VALUE=DATE:20261209
SUMMARY:survodutide: Phase 1 readout est. (NCT07768813)
DESCRIPTION:survodutide\, phase 1\, Obesity.\nStudy: A Study to Compare How
  2 Different Formulations of Survodutide Are Taken up in the Body When Giv
 en by Injection in Healthy Men and Women With and Without Overweight or Ob
 esity\nEstimated primary completion: 8 December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/survodutide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07768813
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05202353-119@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270106
DTEND;VALUE=DATE:20270107
SUMMARY:survodutide: Phase 1 readout est. (NCT05202353)
DESCRIPTION:survodutide\, phase 1\, Obesity.\nStudy: A Study in People With
  Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glu
 cagon Receptor Activity in the Liver\nEstimated primary completion: 6 Janu
 ary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/survodutide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT052
 02353
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407348-119@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270409
DTEND;VALUE=DATE:20270410
SUMMARY:survodutide: Phase 1 readout est. (NCT07407348)
DESCRIPTION:survodutide\, phase 1\, Obesity.\nStudy: A Study in People With
  Overweight or Obesity to Compare How 2 Different Formulations of Survodut
 ide Are Taken up by the Body\nEstimated primary completion: 9 April 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/survodutide#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07407348
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07940244-119@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:survodutide: Phase 1 readout est. (NCT07940244)
DESCRIPTION:survodutide\, phase 1\, Obesity.\nStudy: A Study to Compare How
  Survodutide is Taken up by the Body When Given in 2 Formulations to Peopl
 e With Overweight or Obesity\nEstimated primary completion: 31 October 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/survodutide#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07940244
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07206290-119@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:survodutide: Phase 2 readout est. (NCT07206290)
DESCRIPTION:survodutide\, phase 2.\nStudy: Albuminuria Reduction Study With
  Survodutide Treatment in Kidney Disease\nEstimated primary completion: 30
  November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/survo
 dutide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07206290
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07754461-119@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280117
DTEND;VALUE=DATE:20280118
SUMMARY:survodutide: Phase 3 readout est. (NCT07754461)
DESCRIPTION:survodutide\, phase 3\, Type 2 Diabetes.\nStudy: A Study to Tes
 t Whether Survodutide Helps People With Type 2 Diabetes Control Their Bloo
 d Sugar\nEstimated primary completion: 17 January 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/survodutide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07754461
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07850050-119@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280726
DTEND;VALUE=DATE:20280727
SUMMARY:survodutide: Phase 3 readout est. (NCT07850050)
DESCRIPTION:survodutide\, phase 3\, Obesity.\nStudy: SYNCHRONIZE®-HERA: A 
 Study to Test Whether Survodutide Helps Women Who Are Living With Overweig
 ht or Obesity and Are Going Through or Have Finished Menopause\, to Lose W
 eight\nEstimated primary completion: 26 July 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/survodutide#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07850050
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07850063-119@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20290429
DTEND;VALUE=DATE:20290430
SUMMARY:survodutide: Phase 3 readout est. (NCT07850063)
DESCRIPTION:survodutide\, phase 3\, Obesity.\nStudy: ELEVATE-LIVER: A Study
  to Test Whether Survodutide Helps Improve Heart Structure and Function in
  People With Overweight or Obesity and Fatty Liver Disease\nEstimated prim
 ary completion: 29 April 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/survodutide#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07850063
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632457-119@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20290605
DTEND;VALUE=DATE:20290606
SUMMARY:survodutide: Phase 3 readout est. (NCT06632457)
DESCRIPTION:survodutide\, phase 3\, MASH / NASH.\nStudy: LIVERAGE™ - Cirr
 hosis: A Study to Test Whether Survodutide Helps People With a Liver Disea
 se Called NASH/MASH Who Have Cirrhosis\nEstimated primary completion: 5 Ju
 ne 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/survodutide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0663
 2457
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07855900-119@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20291106
DTEND;VALUE=DATE:20291107
SUMMARY:survodutide: Phase 3 readout est. (NCT07855900)
DESCRIPTION:survodutide\, phase 3\, Obesity.\nStudy: SYNCHRONIZE®-START- A
  Study to Test Whether Survodutide Helps People Living With Overweight or 
 Obesity Who do Not Have Diabetes to Lose Weight\nEstimated primary complet
 ion: 6 November 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /survodutide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07855900
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632444-119@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20311227
DTEND;VALUE=DATE:20311228
SUMMARY:survodutide: Phase 3 readout est. (NCT06632444)
DESCRIPTION:survodutide\, phase 3\, MASH / NASH.\nStudy: LIVERAGE™: A Stu
 dy to Test Whether Survodutide Helps People With a Liver Disease Called NA
 SH/MASH Who Have Moderate or Advanced Liver Fibrosis\nEstimated primary co
 mpletion: 27 December 2031. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/survodutide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06632444
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
